Which company develops and produces ibrutinib?

Ibrutinib (Ibrutinib) is an important drug developed and produced by the American pharmaceutical companyJanssen Pharmaceuticals (a subsidiary of Johnson & Johnson ). This drug represents a major breakthrough in the treatment of leukemia and lymphoma, providing a promising and effective treatment option for patients with certain types of blood cancers.

Janssen Pharmaceuticals is one of the pharmaceutical branches of the US company Johnson & Johnson. It was founded in 1985 and is headquartered in New Lusk, New Jersey, USA. As a leading global pharmaceutical company, Janssen Pharmaceuticals has been committed to developing and producing innovative drugs to meet the different medical needs of patients around the world.

Ibrutinib was developed after long-term scientific research and clinical trials, and was finally approved by the U.S. Food and Drug Administration (FDA) in 2013, becoming one of the first-line drugs for the treatment of chronic lymphocytic leukemia (CLL) and other related blood cancers.

The development of ibrutinib has revolutionized the lives of patients with certain types of leukemia and lymphoma because it provides an oral drug option that is more effective and has fewer side effects than traditional chemotherapy treatments. This drug effectively controls the progression of leukemia and lymphoma by interfering with the signaling mechanism of malignantBlymphocytes.

Ibrutinib is currently on the market in China and is included in medical insurance. The domestic price ranges from 10,000 to 20,000. Due to different medical insurance policies in different places, the price is also different. For specific reimbursement information, please consult the local hospital pharmacy or medical insurance bureau. The cheaper types of ibrutinib abroad are generic drugs, mainly Indian generic drugs, Bangladeshi generic drugs and Laos generic drugs, with prices ranging from a few hundred to several thousand yuan. And the ingredients of generic ibrutinib drugs are basically the same as those of domestic ibrutinib drugs.